english.prescrire.org > Spotlight > Archives : 2018 > Stable angina and antithrombotic drugs

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2018 : 1 | 30 | 60

In the December issue of Prescrire International: Stable angina and antithrombotic drugs

FREE DOWNLOAD Addition of rivaroxaban (Xarelto°) to aspirin increases the risk of serious bleeding, but it has not been shown that the harm-benefit balance of this addition is favourable. Aspirin alone remains the first-choice antithrombotic drug in the majority of patients with coronary disease.
Full text available for free download.


  • In a randomised trial involving around 27 000 patients, most of whom had stable angina, with an average follow-up of 23 months, addition of rivaroxaban to low-dose aspirin led to a significant increase in serious bleeding.
  • Efficacy of rivaroxaban in this situation remains uncertain due to the methodological weaknesses of this trial.

Full text available for free download.

 ©Prescrire 1 December 2018

"Stable angina and antithrombotic drugs. Addition of rivaroxaban to aspirin: uncertain benefits, proven harms" Prescrire Int 2018; 27 (199): 298. (Pdf, free)

Share Share on Facebook Share on Twitter
Partager sur Facebook Partager sur Twitter

Download the full review
Pdf, free

See also:

musculoskeletal disorders
Prescrire Int 2018;
27 (191): 72.
Pdf, subscribers only

Rivaroxaban: agranulocytosis
and Stevens-Johnson syndrome
Prescrire Int  2017;
26 (184) : 186.
Pdf, subscribers only

Rivaroxaban: liver injury
Prescrire Int 2015;
24 (165) : 268.
Pdf, subscribers only

Rivaroxaban 2.5 mg (Xarelto°):
no justification for using this
anticoagulant after an acute
coronary syndrome
(October 2014)